Sugi Predict

Sugi Predict / Compounds / SCHEMBL1753520

SCHEMBL1753520

SCHEMBL1753520

CCOC(=O)c1nnn(-c2ccccc2)c1N

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 2/20 0.75
▸ ALOX12 P18054 1/20 0.75
▸ SMN1; SMN2 Q16637 3/20 0.74
▸ ALDH1A1 P00352 5/20 0.62
▸ HPGD P15428 3/20 0.62
▸ KDM4E B2RXH2 2/20 0.62
▸ HSD17B10 Q99714 1/20 0.62
▸ SLC5A1 P13866 2/20 0.61
▸ SLC5A2 P31639 2/20 0.61
▸ NPC1 O15118 1/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ GAA P10253 2/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ TSHR P16473 1/20 0.54
▸ ADORA2A P29274 1/20 0.53
▸ ADORA1 P30542 1/20 0.53
▸ MAPT P10636 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11333929 0.89 SMN1; SMN2 (0.79) TP53ALOX12SMN1; SMN2ALDH1A1KDM4E
SCHEMBL28591502 0.88 SMN1; SMN2 (0.77) TP53ALOX12SMN1; SMN2ALDH1A1HPGD
SCHEMBL23001698 0.86 SMN1; SMN2 (0.75) TP53ALOX12SMN1; SMN2ALDH1A1HPGD
SCHEMBL10989449 0.86 SMN1; SMN2 (0.75) TP53ALOX12SMN1; SMN2KDM4ESLC5A1
SCHEMBL28604810 0.86 SMN1; SMN2 (0.75) TP53ALOX12SMN1; SMN2ALDH1A1SLC5A1
SCHEMBL6280740 0.86 TP53 (1.00) TP53ALOX12SMN1; SMN2ALDH1A1HPGD
SCHEMBL28691622 0.85 SMN1; SMN2 (1.00) TP53ALOX12SMN1; SMN2ALDH1A1KDM4E
SCHEMBL10374101 0.84 TP53 (0.77) TP53ALOX12SMN1; SMN2ALDH1A1HPGD
SCHEMBL10983744 0.84 TP53 (1.00) TP53ALOX12SMN1; SMN2ALDH1A1HPGD
SCHEMBL10374929 0.83 TP53 (0.75) TP53ALOX12SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024175804-A1 NUCLEAR TRANSPORT MODULATORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-08-29 — — WO disclosed
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 — — US disclosed
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2012-09-06 — — US disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 — — US disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 — — US disclosed
US-8158634-B2 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity IRM LLC (BM) 2012-04-17 — — US disclosed
US-20100137340-A1 FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS GLATTHAR RALF 2010-06-03 — — US disclosed
US-20100137340-A1 FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS GLATTHAR RALF 2010-06-03 — — US disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 — — US disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 — — US disclosed
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2009-10-01 — — US disclosed
WO-2008107418-A1 FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS NOVARTIS AG (CH) 2008-09-12 — — WO disclosed
EP-1807429-A2 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM, LLC (BM) 2007-07-18 — — EP disclosed
WO-2006047516-A2 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY IRM LLC (BM) 2006-05-04 — — WO disclosed
EP-0002562-B1 TRIAZOLO-QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE BEECHAM GROUP PLC (GB) 1981-05-20 — — EP disclosed
US-4223032-A BRONCHODILATOR AGENTS BEECHAM GROUP LIMITED (GB) 1980-09-16 — — US disclosed
EP-0002562-A1 Triazolo-quinoline derivatives, processes for their preparation and their pharmaceutical use BEECHAM GROUP PLC (GB) 1979-06-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137340-A1 FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS GRM1, GRM2, GRM3 TP53 4882/4885ALOX12 3241/4885SMN1; SMN2 1132/4885
US-20120225869-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH TP53 4640/4885ALOX12 600/4885SMN1; SMN2 3746/4885
US-20090247517-A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY CNR1, CNR2, FAAH TP53 4640/4885ALOX12 600/4885SMN1; SMN2 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.